To address widespread media and scientific concerns over the appropriate treatment of TDS with Testosterone Therapy (T Therapy), the Executive Committee of the British Society for Sexual Medicine developed eight consensus statements, based on current scientific evidence to address these controversial issues. These statements were in no-way designed to replace the published evidence-based guidelines on the subject developed by various professional organisations, but to provide specific answers to several current controversial issues. This review examined evidence from Medline, EMBASE and Cochrane searches on HG, T Therapy and cardiovascular safety from 
| Testosterone deficiency is a well-established, significant medical condition
The current International Society for Study of the Ageing Male (ISSAM), 6 European Association of Urology (EAU), 7 International
Society for Sexual Medicine (ISSM), 8 and BSSM 9 definition of HG or
Testosterone Deficiency Syndrome (TDS) is as follows: "A biochemical syndrome associated with advancing age and characterised by a deficiency in serum androgen levels with or without a decreased genomic sensitivity to androgens. It may result in significant alterations in the quality of life and adversely affect the function of multiple organ systems" (Figure 1 ).
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It is worthy of note that the ISSM, 8 EAU 7 and ISSAM 6 guidelines have been updated (2015) , but the Endocrine Society (ES) guidelines date from 2010 11 and therefore do not reflect the vast literature of the amount of literature published in the last 5 years ( Table 1 ).
The most relevant clinical symptoms/signs of HG, as per EAU and ISSM guidelines, are listed in Table 2 . 7, 8 European Association of Urology, ISSM and BSSM guidelines suggest that a level of total testosterone (TT) of <8 nmol/L or free testosterone (FT) of <180 pmol/L (based on two separate 8-11 am levels) requires T Therapy and TT of >12 nmol/L or FT of >225 pmol/L does not. Between these levels, a trial of therapy for a minimum of 6 months should be considered based on symptoms. 7 The ES in 2010
recommended testosterone assessment in a number of high-risk groups, including those with type 2 diabetes mellitus (T2DM) and metabolic syndrome, along with chronic illnesses such as heart failure, renal failure, and human immunodeficiency virus (HIV), and men taking long-term opiate analgesics and anticonvulsants. 11 The ES advised measuring testosterone for erectile dysfunction (ED) and symptomatic HG but stopped short of recommending screening for testosterone in diabetes despite a 40% prevalence. 12 ED and TDS have been shown in studies to be independently associated with reduced quality of life. 13 The European Male Aging Study (EMAS) evaluated over 3000 men aged 40-70 14 according to biochemistry and symptoms and showed that 75% of men maintain normal testosterone levels into old age, suggesting that HG was not merely a function of ageing. The prevalence of secondary HG was 11.8%, with 2% suffering primary HG and 9.5% suffering from compensated HG worthy of observation but not T Therapy.
| Testosterone deficiency has wellestablished symptoms
The most prevalent symptoms of male HG in ageing men are reduced sexual desire and sexual activity, ED, loss of morning erections and hot flushes. composite benefits of these improvements are likely to translate into major quality of life and health economic benefit. 23 Long-term registry studies of over 10 years, however, have shown progressive weight loss and decreased waist circumference and BMI. 24, 25 Cessation of therapy resulted in relapse and reversal of benefits within 6 months, meaning that patients were advised that therapy is likely to be lifelong. 20, 26 Most RCTs of T Therapy were of relatively short duration, 6 months, or occasionally 12 months. T Therapy improved insulin resistance most marked in poorly controlled patients. There are small benefits in lipid metabolism but blood pressure is unaffected. 17, 27 These benefits are more pronounced when combined with lifestyle modifications.
T
Therapy has consistently been shown to improve bone mineral density in the lumbar spine without significant improvement in hip scores.
28
Lower urinary tract symptoms (LUTS) are improved by a mean of 2.2 points in RCTs, 27 and depression scores are improved in uncontrolled studies. 29 Most RCTs were conducted over a 3-to 12-month duration and evidence strongly suggests that trials of T Therapy should be for a minimum of 6 months.
17
Although HG is often associated with reduced fertility, 7 T Therapy in younger men reduces LH and FSH levels and frequently causes infertility after 6-12 months which is reversible in 60-70% of men within 9-12 months. 28 Where fertility is an important issue for men with HG, then alternative therapy such as HCG or Clomiphene citrate (unlicensed in men) should be considered. 
| There is no scientific basis for withholding T Therapy from men on the basis of age
Although it is commonly stated that testosterone declines with age, evidence from EMAS suggests that there is little decline in T levels between 40 and 75 in non-obese men. 14 In fact, over 80% of men will maintain normal T levels into old age, suggesting that the term "age-related hypogonadism" is misleading. There is a fall in FT and bioavailable T secondary to the rise in SHBG with age, but primarily the increase in TD with age is related to increasing prevalence of obesity, T2DM, and chronic illness. The clinical and physiological responses to T Therapy, especially increased muscle mass and strength, are seen in both younger and older men. 22 These benefits may be of greater clinical and economic significance in older men, as reduced muscle mass and lower limb strength are strongly related to frailty and increased rate of falls. 
| Testosterone deficiency is associated with increased cardiovascular and all-cause mortality
There is increasing evidence from multiple long-term studies that HG is associated with increased cardiovascular and all-cause mortality.
F I G U R E 2
Trend for reduction in all-cause mortality in T2DM appears greatest in men over 75 33 . Mortality in patients categorised by: Group A = normal testosterone; B= low testosterone untreated; C = low testosteron A 10-year study from Western Australia involving 3690 older men concluded that TT and FT levels in the normal range were associated with decreased all-cause and cardiovascular mortality, for the first time suggesting that both low and high levels were associated with all-cause mortality and higher levels of dihydrotestosterone (DHT)-reduced cardiovascular risk. 35 A recent Swedish study with a 14-year follow-up suggested a strong association between baseline testosterone and incident myocardial infarction (MI). 36 Araujo et al. concluded
that most studies involved issues in cohort selection and choice. 37 They concluded that a decrease of 2.1 standard deviations in TT was associated with a 25% increase in mortality. Haring et al. looked at the data in terms of several statistical models and found that even after strict adjustment for comorbidities, there was a consistent link between mortality risk and testosterone level throughout the studies without proving causation 38 (Table 3) . Similar conclusions were drawn from meta-analyses by Ruige et al. 39 and most recently Corona et al., 40 where the focus was on cardiovascular disease as opposed to all-cause mortality. All conclude that there is a consistent link between low testosterone and cardiovascular disease incidence and mortality, but this did not prove a pathogenic link, but Muraleedharan et al. concluded that low testosterone could be a "marker" of illness.
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Six published studies generally involving small samples have shown that low TT and FT are associated with coronary artery disease (CAD), and four have shown no association. 42 Four studies have shown inverse associations between low TT and FT ( 
| The evidence does not support an increased cardiovascular risk associated with T Therapy
Possible mechanisms for adverse cardiovascular disease events with T Therapy may arise through a 6% increased rate of polycythaemia, related to multiple mechanisms. 48 By conversion to oestradiol, there is direct stimulation of erythropoiesis in the bone marrow. Testosterone also stimulates erythropoietin synthesis in the kidney and in turn increases erythropoiesis and T-induced increase of hepatic transcription factors with decreased hepcidin and as a consequence of increased iron usage. 49 It has been suggested that supra-physiological levels associated with short-acting injections may exaggerate this effect 27 as may the conversion of gels to DHT by the action of 5-alpha reductase in the skin. 28 A full list of adverse events associated with T Therapy is shown in Table 4 . These include polycythaemia with increase of haematocrit and haemoglobin, gynaecomastia, loss of head hair, acne and other skin disorders, increased aggressiveness and hyper sexuality. heart failure. 4 Studies with high-dose testosterone use in body builders have shown reductions in high-density lipoprotein cholesterol, 45 whereas randomised studies of appropriate dose T Therapy have shown minimal adverse effect of T Therapy or even improvement. covariates) reversed the trend and concluded that there was a greater risk in the T Therapy group. There were concerns that 1132 patients experiencing events were excluded because they were prescribed T Therapy after the event when surely these should have been included in the untreated group, increasing the events by 70%. Furthermore, there were no data on whether there was a correct diagnosis of TDS before T Therapy, none on compliance and some patients did not continue T Therapy, 'and mean TT levels on T Therapy were at lower end of normal suggesting many were under treated. When challenged, the authors revised the number to 132, but conceded that 104 women had wrongly been included in the results.
Finkle et al. 3 studied prescribing data in men treated with T Therapy, but with no data on blood results or symptoms. Non-fatal coronary events were the major end-point, assessed in the 12 months before and 3 months after therapy, even though benefits of T Therapy would take much longer and other studies had excluded the first 3 months from analysis as the events would be likely to be related to the pre-existing condition. Most importantly, fatal cardiovascular events and all-cause mortality data were not collected despite the major impact of T Therapy in other studies being seen on mortality and not event numbers. Twelve-month posttreatment data were collected but not presented. The event rates within the groups prior to treatment were strangely identical. They reported a small increase in non-fatal cardiac events in men commenced on T Therapy, more marked in those with increased risk. Overall events in the study were lower than predicted from comparable research. They failed to report deaths, failing to realise that a treatment that reduced mortality was likely to increase non-fatal events. The design was not prospective, casting doubts on the validity of retrospective assessment for the pre- hypogonadal men, with 372 on T Therapy. 45 The cumulative mortality was 21% in the untreated group vs 10% in the treated group, with the greatest effect in younger men and those with T2DM. Both articles were criticised for possible selection bias, but the strengths included reliable pretreatment diagnosis and accurate reporting of medications.
Hackett et al. 33 followed up 857 men with T2DM for 4 years following baseline testosterone measurement. Patients had been randomised to long-acting testosterone undecanoate (TU) or placebo assessment during a randomised controlled study. The investigators confirmed that low baseline TT and FT were associated with increased all-cause mortality over a 4-year follow-up. They reported that T Therapy and the use of phosphodiesterase 5 inhibitors (PDE5Is) were independently associated with reduced all-cause mortality, with the greatest benefit from both T Therapy and PDE5Is being seen in older men.
Baillargeon et al. 52 compared acute myocardial infarction rates for 6355 men over 8 years, receiving at least one testosterone injection compared with a matched placebo group, and found no overall increase in events. In the quartile at greatest risk, there was a significant reduction in events and mortality. The authors found no increased risk from venous thromboembolism. The same authors have shown significant reductions in acute hospital admission in men treated with T Therapy compared with an untreated cohort. 52 Anderson et al. 53 correlated with testosterone supplement use. Primary outcomes were a composite of death, non-fatal MI, and stroke, MACE and death alone. T Therapy in men with low testosterone was associated with reduced MACE and death over 3 years compared with no or ineffective supplementation. This study suggested that the favourable impact of T Therapy was predominantly on mortality, rather than number of events, and benefits were associated with achieving therapeutic levels of testosterone, with no suggestion of increased risk with sustained higher serum levels. The same group 53 have shown significant reduction in cardiovascular events in a cohort of hypogonadal men with angiographically diagnosed CAD.
Sharma et al. 46 retrospectively evaluated 83,010 male veterans with documented low TT levels. The subjects were categorised into three groups: T Therapy with resulting normalisation of TT levels (group 
| A major research initiative to explore the benefits of T Therapy in cardio-metabolic disease is overdue
Most reviews conclude that a long-term RCT is required to definitively answer the complex issues around T Therapy.
The Testosterone for the prevention of Diabetes Mellitus (T4DM) (t4dm.org.au) study in Australia 58 involves younger (n=1500), obese men with glucose intolerance and testosterone levels of 8-11 nmol/L, randomised to long-acting TU or placebo, to establish whether T Therapy will reduce the development of T2DM. This might provide important answers for younger men, but will not answer questions about risk/benefits in older populations.
It is unlikely that definitive answers will be found to the many questions raised in this article without huge independent funding.
With considerable evidence of benefit associated with T Therapy for HG, it is unlikely that ethical approval will be granted for sufficiently powered placebo-controlled studies lasting several years.
| CONCLUSIONS
Testosterone deficiency is a well-established, significant medical condition with defined clinical symptoms and is associated with increased cardiovascular and all-cause mortality. Treatment is effective, evidence based and safe. Recent studies suggest that T Therapy resulting in sustained normalisation of serum levels is probably associated with reduced mortality. Currently available T Therapy treatment modalities and their advantages and disadvantages are outlined in Table 5 .
T Therapy is associated with multiple benefits maybe highly relevant to the patient but underestimated by specialist physicians focused on specific outcomes. Until the definitive well-powered long-term study is published, we hope that these consensus statements will enable patients to be treated on best available evidence (Table 6 ). 
